Abstract: Objective To explore the safety and efficacy of paclitaxel combined with nedaplatin in the treatment of patients with advanced esophageal cancer.Methods 48 patients with advanced esophageal cancer were randomly divided into two groups,and they were treated with pa-clitaxel combined with nedaplatin or cisplatin respectively.Paclitaxel combined with nedaplatin group:130 mg /m2 paclitaxel,intravenous drip on d1 and d8;80 mg /m2 nedaplatin,intravenous drip on d1.Paclitaxel combined with cisplatin group:paclitaxel group:130 mg /m2 paclitaxel,in-travenous drip on d1 and d8;80 mg /m2 cisplatin,intravenous injection on d1.3 weeks were consid-ered as a cycle of chemotherapy in both groups.Short-term efficacy,survival time and adverse re-actions were observed after treatment in both groups.Results RR in paclitaxel combined with nedaplatin group was slightly higher than paclitaxel combined with nedaplatin group.Survival rate within 9 months in paclitaxel combined with nedaplatin group was significantly higher than paclitax-el combined with nedaplatin group,and survival rates within 6,12 and 18 months were slightly higher than paclitaxel combined with nedaplatin group.The main adverse reactions in both groups were bone marrow suppression,gastrointestinal reactions and alopecia mainly at grades Ⅰ~Ⅲ. Conclusion For advanced esophageal cancer patients without chemotherapy contraindications,the regimen of paclitaxel combined with nedaplatin can effectively improve the quality of life,prolong the life and improve clinical efficacy.